BridgeMD
BIOlogical treatment GRAdual Interval Longing in severe Asthma (BIO-GRAIL)
EU CTIS ID: 2025-524741-28-00
What this study is testing
To evaluate the feasibility and safety of gradual interval prolonging of biologics during ~1 year in patients with severe asthma
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Receiving biological treatment (mepolizumab, reslizumab, benralizumab, dupilumab, or tezepelumab) for more than 12 months
- ≥18 years of age
- 0 or 1 exacerbation in the past 12 months
- Baseline ACQ < 2.0
- Blood eosinophil count ≤0.3 +10^9/L for anti-IL-5(R)/Tezepelumab, ≤1.5 +10^9/L for Dupilumab
You likely can't join if
- Uncontrolled asthma (>1 exacerbation in the past 12 months or ACQ > 2.0)
- Pregnancy
- Intention to become pregnant within the next 12 months
- Biologic administration intervals already prolonged beyond the approved regimen according to the SmPC at the patient’s request
- Inability to understand and communicate in Dutch or English, both spoken and written
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.